Medtronic To Spin Out Diabetes Unit As New Products Solidify Turn-Around Story

First Big Test Could Be US Launch For Simplera CGM In Second Half Of 2025

 
• By Shubham Singh

Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.

During fiscal Q4, Medtronics’ diabetes segment grew 12% organically – its sixth consecutive quarter of double-digit growth – driven by continued adoption of the MiniMed 780G and CGM sensor sales.

More from Strategy

More from Device Area